Experimental Cholesterol Drug Does Not Cut Risk for Cardiovascular Events — Physician’s First Watch

Medical News |
May 18, 2017

Experimental Cholesterol Drug Does Not Cut Risk for Cardiovascular Events

By the Editors

Evacetrapib, an experimental cholesterol ester transfer protein inhibitor, raises HDL cholesterol and lowers LDL cholesterol — but does not reduce risk for cardiovascular events — according to an industry-funded, phase 3 trial in the New England Journal of Medicine.

Dr. Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, offers his take on the findings at the link below.

Reader Comments (1)

David Foster, MD Physician, Family Medicine/General Practice, Oregon

There seems to be ever increasing evidence that a major effect of statins is protection of endothelial integrity and function and that the HDL and LDL effects may be secondary. Atromid-S was one of the first drugs that improved lipid assays but also increased mortality. Now we see more that are either ineffective or harmful.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.